[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651372":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":39,"responsibleParty":71,"collaborators":74,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":23,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":26,"enrollmentInfo":87,"targetDuration":26,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":101,"whyStopped":26,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"STRIDE Intervention","EXPERIMENTAL","Participants randomized to STRIDE will receive a brief, manualized, videoconference intervention with six weekly one-hour sessions in small groups of two to three patients and two individual semi-structured telephone check-ins. Participants will complete questionnaires at baseline, and 3, 6, and 12 months post-baseline.",[13],"Behavioral: STRIDE",{"label":15,"type":16,"description":17,"interventionNames":18},"Usual Care","ACTIVE_COMPARATOR","Participants randomized to usual care will receive regular oncology follow-up care which entails one follow-up visit with the primary treating oncologist after prescription of AET and as needed contact with a nurse practitioner or RN for symptom control or other medication related questions. Participants will also complete questionnaires at baseline, and 3, 6, and 12 months post-baseline. Participants will be offered one optional STRIDE intervention visit upon completion of the 12-month questionnaire.",[19],"Behavioral: Usual Care",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BEHAVIORAL","STRIDE","STRIDE is a 6-session patient-directed cognitive behavioral therapy (CBT)-based psychosocial intervention that targets coping with and managing AET side effects. The intervention incorporates psychoeducation, problem-solving, cognitive restructuring, relaxation training, symptom management skills training, coping effectiveness training, and mindfulness techniques.",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Participants randomized to usual care will receive regular oncology follow-up care which entails one follow-up visit with the primary treating oncologist after prescription of AET and as needed contact with a nurse practitioner or RN for symptom control or other medication related questions.",[15],[31],{"name":32,"affiliation":5,"role":33},"Jamie M Jacobs, PhD","PRINCIPAL_INVESTIGATOR",[35],{"name":32,"role":36,"phone":37,"phoneExt":26,"email":38},"CONTACT","(617) 643-1777","jjacobs@mgh.harvard.edu",[40,59],{"facility":41,"status":26,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Moffitt Cancer Center","Tampa","Florida","33612","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-82.45843,27.94752,{"lat":51,"lon":50},[54,58],{"name":55,"role":36,"phone":56,"phoneExt":26,"email":57},"Laura Oswald, PhD","(813) 745-1338","Laura.Oswald@moffitt.org",{"name":55,"role":33,"phone":26,"phoneExt":26,"email":26},{"facility":5,"status":26,"city":60,"state":61,"zip":62,"country":45,"countryCode":46,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Boston","Massachusetts","02114",{"type":48,"coordinates":64},[65,66],-71.05977,42.35843,{"lat":66,"lon":65},[69,70],{"name":32,"role":36,"phone":37,"phoneExt":26,"email":38},{"name":32,"role":33,"phone":26,"phoneExt":26,"email":26},{"type":33,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Jamie Jacobs","Principal Investigator",[75],{"name":76,"class":77},"National Cancer Institute (NCI)","NIH","100651372","telehealth-intervention-for-symptom-management-and-adherence-to-adjuvant-endocrine-therapy-100651372",false,"NCT07759947","Telehealth Intervention for Symptom Management and Adherence to Adjuvant Endocrine Therapy","STRIDE: Evidence-Based Telehealth Intervention for Symptom Management and Adherence to Adjuvant Endocrine Therapy","Inclusion Criteria:\n\n* Female ≥ 21 years old\n* Diagnosis of early-stage (0-IIIb), hormone receptor positive (ER+\u002FPR+) breast cancer\n* Completed primary treatment (surgery, chemotherapy, and\u002For radiation)\n* Within 3 to 12 months of starting oral adjuvant endocrine therapy (AET)\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Ability to read and respond in English or Spanish\n* Distress about AET ≥ 4 on a 0-10 scale\n\nExclusion Criteria:\n\n* Cognitive impairment, uncontrolled psychosis, or serious mental illness prohibiting participation in the study as per the judgment of the treating oncologist\n* Enrolled in a clinical trial for AET","FEMALE","21 Years",{"count":88,"type":89},400,"ESTIMATED","INTERVENTIONAL",[92],"NA","The goal of this study is to demonstrate the efficacy of an evidence-based, small-group, telehealth intervention ('STRIDE') for improving patients' ability to cope with side effects from adjuvant endocrine therapy (AET) and adhere to AET medication regimens for patients with hormone-sensitive breast cancer.",[95],"Hormone Receptor Positive Breast Cancer",[95,97,98,99,100],"Adjuvant Endocrine Therapy Adherence","Coping","Supportive Care","Behavioral Intervention","NOT_YET_RECRUITING","2026-08-07",{"date":104,"type":105},"2026-08-12","ACTUAL",{"date":107,"type":89},"2027-02-01",{"date":109,"type":89},"2031-06-01",{"name":5,"class":6},2]